Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| LX Medical | UNKNOWN |
Not provided
Not provided
Not provided
This is a new, commercially available, over-the-counter fiber supplement that combines 8 fibers. The varied nature of the fibers in this product is designed to create a more diverse microbiome (bacteria that live within the human GI tract). In general, the more diverse the microbiome the less inflammatory the gut. The purpose of this study is to evaluate the effects of a new fiber product on bloating, gas, and bowel movements.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fiber supplemenmt | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fiber supplement | Dietary Supplement | Subjects that meet the inclusion criteria and with symptoms appropriate for fiber supplementation are eligible to participate. Participants will be instructed to use the fiber product (NutraLieve) as currently labeled; start with a dosage of 4-5 grams per day (one heaping teaspoon), initially taken once daily, increasing up to 3 heaping teaspoons a day (maximum dose 15 grams/day) on an as needed basis.Participants will be prospectively assessed for symptoms at baseline and at 6 weeks.
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of bowel movement | - The primary endpoint, number of bowel movements, will be assessed by bowel movements in the last 72-hour period at baseline and at 6 weeks, by patient recall/diary. | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Bloating | - Reduction in bloating will be assessed using analog scales, also by 72-hour recall at baseline and at 6 weeks, by patient recall/diary. | 6 weeks |
| Gas | Reduction in gas will be assessed using analog scales, also by 72-hour recall at baseline and at 6 weeks, by patient recall/diary. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Robert Ganz, MD | Contact | 802-272-7374 | bob@ganzindustries.com | |
| Claudia Morr, MD | Contact | 612-721-3976 | morr.c@bellintlabs.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| XL Medical | Edina | Minnesota | 55435 | United States |
Subject's demographics and measured outcomes
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 6 weeks |